Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Adalimumab
/ therapeutic use
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antibodies, Viral
/ immunology
Biological Products
/ therapeutic use
COVID-19
/ epidemiology
COVID-19 Serological Testing
Child
Colitis, Ulcerative
/ drug therapy
Crohn Disease
/ drug therapy
Enzyme-Linked Immunosorbent Assay
Female
Gastrointestinal Agents
/ therapeutic use
Hospitalization
Humans
Immunosuppressive Agents
/ therapeutic use
Inflammatory Bowel Diseases
/ drug therapy
Infliximab
/ therapeutic use
Italy
/ epidemiology
Male
Middle Aged
SARS-CoV-2
/ immunology
Seroepidemiologic Studies
Thalidomide
/ therapeutic use
Ustekinumab
/ therapeutic use
Young Adult
Biologic therapy
IBD
SARS-CoV-2
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
20
10
2020
revised:
24
12
2020
accepted:
31
12
2020
pubmed:
12
1
2021
medline:
12
3
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
Patients receiving biologic therapies are at risk for viral infections. This study investigated the impact of the SARS-CoV-2 infection and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD) treated with biologic drugs. Information on demography, co-morbidities, clinical data regarding IBD, symptoms suggestive of the SARS-CoV-2 infection, close contacts with SARS-CoV-2 positive patients, hospitalization, and therapies administered for COVID-19 was collected for all patients who were being treated with biologic drugs. All patients underwent SARS-CoV-2 antibody testing. Two hundred and fifty-nine patients (27 children) with a mean age of 42.2 ± 16.7 years (range 9 - 88) and a mean duration of disease of 13.4 ± 10 years (range 0.2 - 49) were enrolled. One hundred four patients (40.2%) had ulcerative colitis, and 155 (59.8%) had Crohn's disease. About the therapy: 62 patients were receiving infliximab, 89 adalimumab, 20 golimumab, 57 vedolizumab, 27 ustekinumab, 1 thalidomide, and 3 an experimental compound. The mean Charlson Comorbidity Index was 2. Thirty-two patients (12.3%) reported respiratory symptoms, and 2 of them were hospitalized (0.77%). Two patients resulted positive for IgG against SARS-CoV-2 (0.77%). In patients with IBD, treatment with biologic drug does not represent a risk factor for the SARS-CoV-2 infection.
Sections du résumé
BACKGROUND
Patients receiving biologic therapies are at risk for viral infections. This study investigated the impact of the SARS-CoV-2 infection and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD) treated with biologic drugs.
METHODS
Information on demography, co-morbidities, clinical data regarding IBD, symptoms suggestive of the SARS-CoV-2 infection, close contacts with SARS-CoV-2 positive patients, hospitalization, and therapies administered for COVID-19 was collected for all patients who were being treated with biologic drugs. All patients underwent SARS-CoV-2 antibody testing.
RESULTS
Two hundred and fifty-nine patients (27 children) with a mean age of 42.2 ± 16.7 years (range 9 - 88) and a mean duration of disease of 13.4 ± 10 years (range 0.2 - 49) were enrolled. One hundred four patients (40.2%) had ulcerative colitis, and 155 (59.8%) had Crohn's disease. About the therapy: 62 patients were receiving infliximab, 89 adalimumab, 20 golimumab, 57 vedolizumab, 27 ustekinumab, 1 thalidomide, and 3 an experimental compound. The mean Charlson Comorbidity Index was 2. Thirty-two patients (12.3%) reported respiratory symptoms, and 2 of them were hospitalized (0.77%). Two patients resulted positive for IgG against SARS-CoV-2 (0.77%).
CONCLUSIONS
In patients with IBD, treatment with biologic drug does not represent a risk factor for the SARS-CoV-2 infection.
Identifiants
pubmed: 33423942
pii: S1590-8658(21)00002-5
doi: 10.1016/j.dld.2020.12.120
pmc: PMC7834247
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antibodies, Viral
0
Biological Products
0
Gastrointestinal Agents
0
Immunosuppressive Agents
0
Thalidomide
4Z8R6ORS6L
golimumab
91X1KLU43E
vedolizumab
9RV78Q2002
Infliximab
B72HH48FLU
Ustekinumab
FU77B4U5Z0
Adalimumab
FYS6T7F842
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-282Informations de copyright
Copyright © 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest None declared.